Citations

Clear

1053 citation(s) found for "Andre, F".

Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Rugo, Hope S. , Huober, Jens , Masuda, Norikazu , Sohn, Joohyuk , Barriga, Susana , Cox, Joanne, Masuda, Norikazu , Rugo, Hope S , Sohn, Joohyuk , García-Sáenz, José Á. , André, Valérie , Goetz, Matthew P.

Mayo Clinic

The Oncologist | September 21, 2020 | Volume: 26 | Issue: 1 | Pages: e53-e65

10.1002/onco.13531 | PMID 32955138 Get It

Abstract Background Abemaciclib demonstrated efficacy in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Here we provide a comprehensive summary of the most common adverse events (AEs), their management, and whether AEs or dose reductions influenced progression-free survival (PFS), in the MONARCH 2 and 3 trials. Materials and Methods Incidence of the most clinically relevant AEs, management, and outcomes were summarized. Time-dependent covariate analyses examined the impact of dose reductions on PFS. PFS was estimated for patients with and without early onset of diarrhea or neutropenia. Results The most frequently reported AE was diarrhea, with clinically significant diarrhea (grade ≥2) reported for 42.8% of patients taking abemaciclib. Median time to onset was 1 week, and duration ranged from 6 to 12 days, depending on grade and study. Diarrhea was adequately managed by antidiarrheal medication (72.8%), dose omissions (17.3%), and reductions (16.7%). The highest rates of grade ≥2 diarrhea were observed in the first cycles and decreased in subsequent cycles. Neutropenia (grade ≥3) occurred in 25.4% of abemaciclib-treated patients. Neutropenia resolved with dose omissions (16.8%) and/or dose reductions (11.2%). Incidence of febrile neutropenia (0.7%) or other relevant grade ≥3 hematological events (<9%) was low. Venous thromboembolic events (5.3%) were primarily treated with anticoagulants. Interstitial lung disease/pneumonitis (3.4%) was treated with corticosteroids and/or antibiotics. PFS benefit of abemaciclib was not impacted by dose reductions or early onset of toxicities. Conclusion Abemaciclib was generally well tolerated. The most common AEs were effectively managed by supportive medications, and/or dose adjustments, with no detriment to PFS. Implications for Practice Treatment with abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitors is generally well tolerated in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. In MONARCH 2 and MONARCH 3, any-grade diarrhea and grade ≥3 neutropenia were effectively managed with supportive medication and/or dose adjustment. Venous thromboembolic events were treated with anticoagulants and did not often require treatment discontinuation. Interstitial lung disease/pneumonitis was infrequent and treated with corticosteroids and/or antibiotics. Clinicians should be aware of and implement management strategies, including dose adjustments according to local labels, for commonly occurring and serious adverse events to ensure continued treatment and optimize clinical benefit/risk ratio.
Bronchiolar Adenoma/Pulmonary Ciliated Muconodular Papillary Tumor
Shirsat, Hemlata , Zhou, Fang , Rekhtman, Natasha , Saqi, Anjali , Argyropoulos, Kimon V. , Azour, Lea , Simms, Anthony, Melamed, Jonathan , Hung, Yin P. , Roden, Anja C. , Moreira, André L. , Narula, Navneet , Saqi, Anjali , Argyropoulos, Kimon , Azour, Lea , Hung, Yin P , Chang, Jason C. , Mino-Kenudson, Mari A.

Mayo Clinic

American Journal of Clinical Pathology | September 11, 2020 | Volume: 155 | Issue: 6 | Pages: 832-844

10.1093/ajcp/aqaa194 | PMID 33313677 Get It

Abstract Objectives To describe the histologic features that are helpful in the diagnosis of the rare bronchiolar adenomas/ciliated muconodular papillary tumors (BAs/CMPTs) during intraoperative consultation. Methods Multi-institutional retrospective review of frozen sections of 18 BAs/CMPTs. Results In 14 of 18 cases, BA/CMPT was the primary reason for sublobar lung resection, and in 4 cases, BA/CMPT was an incidental finding intraoperatively for resections performed for carcinoma in other lobes. There were 11 proximal-type/classic BAs/CMPTs and 7 distal-type/nonclassic BAs/CMPTs. Only 3 (16.7%) of 18 were correctly diagnosed at the time of frozen section, all of which were proximal type/classic. The remainder were diagnosed as adenocarcinoma (n = 7); invasive mucinous adenocarcinoma (n = 1); non–small cell lung carcinoma (n = 1); cystic mucinous neoplasm, favor adenocarcinoma (either mucinous or colloid type) (n = 1); favor adenocarcinoma, cannot exclude CMPT (n = 1); atypical proliferation (n = 2); mucinous epithelial proliferation (n = 1); and mucous gland adenoma (n = 1). Conclusions BA/CMPT can potentially be misdiagnosed as carcinoma during intraoperative consultation. On retrospective review of the frozen sections, the presence of the following may help to avoid misdiagnosis: a mixture of bland ciliated columnar cells, mucinous cells, and, most important, a basal cell layer, as well as a lack of necrosis, significant atypia, and mitoses.
Global epigenetic alterations of mesenchymal stem cells in obesity: the role of vitamin C reprogramming
Afarideh, Mohsen , Thaler, Roman , Khani, Farzaneh , Jordan, Kyra L., Conley, Sabena M., Saadiq, Ishran M. , Obeidat, Yasin , Eirin, Alfonso , Zhu, Xiang-Yang, Wijnen, André J. van , Lerman, Lilach O. , Saadiq, Ishran M , Obeidat, Yasin , Pawar, Aditya S. , van Wijnen, Andre J , Eirin, Alfonso , Tang, Hui Ru , Lerman, Amir

Mayo Clinic

Epigenetics | September 6, 2020 | Volume: 16 | Issue: 7 | Pages: 705-717

10.1080/15592294.2020.1819663 | PMID 32893712 Get It

Potential interactions of SARS‐CoV‐2 with human cell receptors in the skin: Understanding the enigma for a lower frequency of skin lesions compared to other tissues
Criado, Paulo Ricardo , Pincelli, Thaís , Criado, Roberta Fachini Jardim , Pincelli, T , Criado, P R , Abdalla, Beatrice Martinez Zugaib , Belda, Walter

Mayo Clinic

Experimental Dermatology | August 31, 2020 | Volume: 29 | Issue: 10 | Pages: 936-944

10.1111/exd.14186 | PMID 32867008 Get It

AbstractThe severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) represents a new public health problem, with a total of 10.577.263 documented COVID‐19 cases worldwide and 513.441 deaths up to the present date. Few cases of disease‐related cutaneous manifestations have been reported in the literature, and such manifestations are scarce. Integumentary manifestations from COVID‐19 include exanthemas and papular dermatoses, urticarial eruptions, atopic dermatitis, vesiculobullous lesions and skin signs of hypercoagulable states, such as acral ischaemia, livedo and retiform purpura. Most common extracutaneous manifestations from the disease include headache, cough, anosmia, ageusia, fever, dyspnoea, nausea, diarrhoea and cardiovascular events. The objectives of this review were to discuss the role of human cell receptors described as interaction targets of SARS‐CoV‐2, as well to understand the current state of knowledge on skin expression of these receptors, in order to substantiate future research. The authors present a thorough literature review on SARS‐CoV‐2 and its possible interaction with cell receptors and human tissues including the skin. They discuss a molecular hypothesis to explain the lower prevalence of dermatological manifestations from direct SARS‐CoV‐2 infection. Distinct human cell receptors binding the virus appear to be less expressed in the skin compared to other organs. Additionally, the presence of resolvins and the disintegrin metalloprotease ADAM17 provide a putative protection to the skin, explaining the majority of COVID‐19 manifestations to be extracutaneous. This review represents an excellent opportunity for future studies using skin biopsies from COVID‐19 patients to investigate molecular expression in the pathophysiology of cutaneous manifestations of the disease.
Quality indicators for the care and outcomes of adults with atrial fibrillation
Arbelo, Elena , (Chair), Drossart, Inga , Dwight, Jeremy, Hills, Mellanie True , Hindricks, Gerhard , Lane, Deirdre A. , Lau, Dennis H. , Lettino, Maddalena , Lobban, Trudie , Pak, Hui‐Nam , Potpara, Tatjana , Sáenz, Luis Carlos , Gelder, Isabelle C. Van , Varosy, Paul D. , Gale, Chris P , Dagres, Nikolaos , (Co-chair), Reviewers, coordinator), (review, Defaye, Pascal , Lenarczyk, Radosław , Providência, Rui , Palmero, María José Guerra , Takahashi, Yoshihide , Sarkozy, Andrea , Glotzer, Taya V. , Kusumoto, Fred M, Dagres, Nikolaos , Providencia, Rui , Arbelo, Elena , Lane, Deirdre A , (Chair), Aktaa, Suleman , Bollmann, Andreas , d'Avila, Andre , Kusumoto, Fred , Lip, Gregory Y H , (Co-chair), Reviewers, Bovéda, Serge , coordinator), (review, Deneke, Thomas , Conte, Giulio , Pisani, Cristiano , Nava, Santiago , Oliveira, Mário

Mayo Clinic

EP Europace | August 31, 2020 | Volume: 23 | Issue: 4 | Pages: 494-495

10.1093/europace/euaa253 | PMID 32860039 Get It

Abstract Aims To develop quality indicators (QIs) that may be used to evaluate the quality of care and outcomes for adults with atrial fibrillation (AF). Methods and results We followed the ESC methodology for QI development. This methodology involved (i) the identification of the domains of AF care for the diagnosis and management of AF (by a group of experts including members of the ESC Clinical Practice Guidelines Task Force for AF); (ii) the construction of candidate QIs (including a systematic review of the literature); and (iii) the selection of the final set of QIs (using a modified Delphi method). Six domains of care for the diagnosis and management of AF were identified: (i) Patient assessment (baseline and follow-up), (ii) Anticoagulation therapy, (iii) Rate control strategy, (iv) Rhythm control strategy, (v) Risk factor management, and (vi) Outcomes measures, including patient-reported outcome measures (PROMs). In total, 17 main and 17 secondary QIs, which covered all six domains of care for the diagnosis and management of AF, were selected. The outcome domain included measures on the consequences and treatment of AF, as well as PROMs. Conclusion This document defines six domains of AF care (patient assessment, anticoagulation, rate control, rhythm control, risk factor management, and outcomes), and provides 17 main and 17 secondary QIs for the diagnosis and management of AF. It is anticipated that implementation of these QIs will improve the quality of AF care.
Chronic spontaneous urticaria exacerbation in a patient with COVID‐19: rapid and excellent response to omalizumab
Criado, Paulo Ricardo , Criado, Roberta Fachini Jardim , Pincelli, Thaís , Yoshimoto, Thais Akemi , Naufal, Gabriela G. A., Abdalla, Beatrice Martinez Zugaib , Pincelli, Thais P, Abdalla, Beatrice M Z , Pincelli, T , Criado, P R

Mayo Clinic

International Journal of Dermatology | August 28, 2020 | Volume: 59 | Issue: 10 | Pages: 1294-1295

10.1111/ijd.15134 | PMID 32808279 Get It

Digital Regenerative Medicine and Surgery Pedagogy for Virtual Learning in the Time of COVID-19
Wyles, Saranya P. , Meyer, Fredric B. , Hayden, Richard E. , Scarisbrick, Isobel A. , Terzic, André , Hayden, Richard , Scarisbrick, Isobel A , Terzic, Andre

Mayo Clinic

Regenerative Medicine | August 26, 2020 | Volume: 15 | Issue: 8 | Pages: 1937-1941

10.2217/rme-2020-0106 | PMID 32844717 Get It

Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study
James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Sylte, Dillon O , Bertolacci, Gregory J, Cunningham, Matthew , LeGrand, Kate E , Abdelalim, Ahmed , Abdulkader, Rizwan Suliankatchi , Abedi, Aidin , Abegaz, Kedir Hussein , Eshete, Akine , Abushouk, Abdelrahman Ibrahim , Adebayo, Oladimeji , Advani, Shailesh M, Agudelo‐Botero, Marcela , Ahmad, Tauseef , Aichour, Miloud Taki Eddine, Alahdab, Fares , Alanezi, Fahad , Alema, Niguse Meles , Wassihun, Biresaw , Ali, Beriwan Abdulqadir, Alipour, Vahid, Almasri, Nihad A. , Altirkawi, Khalid A , Amer, Yasser Sami , Andrei, Cătălina Liliana , Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Anvari, Davood , Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Ariani, Filippo , Arora, Amit , Quintanilla, Beatriz Paulina Ayala , Ayano, Getinet , Ayanore, Martin Amogre , Azarian, Ghasem , Badawi, Alaa, Badiye, Ashish , Baig, Atif Amin , Bairwa, Mohan , Bakhtiari, Ahad , Banerjee, Srikanta , Banik, Palash Chandra , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Barzegar, Akbar , Belete, Habte , Bennett, Derrick , Berhe, Kidanemaryam , Bhagavathula, Akshaya Srikanth , Bhardwaj, Pankaj , Bhat, Anusha Ganapati , Bhattacharyya, Krittika , Bhutta, Zulfiqar A , Bibi, Sadia , Bijani, Ali , Borschmann, Rohan , Borzì, Antonio Maria , Braithwaite, Dejana , Брико, Н. И. , Brugha, Traolach , Budhathoki, Shyam Sundar , Car, Josip , Cárdenas, Rosario , Carvalho, Félix , Castaldelli-Maia, João Maurício , Castañeda-Orjuela, Carlos A , Castelpietra, Giulio , Catalá-López, Ferrán , Cerin, Ester , Chandan, Joht Singh , Chapman, Jens R. , Chattu, Vijay Kumar , Chattu, Soosanna Kumary , Chaudhary, Neha , Cho, Daniel , Choi, Jee-Young J, Chowdhury, Mohiuddin Ahsanul Kabir , Christopher, Devasahayam Jesudas , Chu, Dinh‐Toi , Costa, Vera Marisa , Dávila-Cervantes, Claudio Alberto , Leo, Diego De, Demoz, Gebre Teklemariam , Demsie, Desalegn Getnet , Deribe, Kebede , Desai, Rupak , Nasab, Mostafa Dianati, Silva, Diana Dias da , Forooshani, Zahra Sadat Dibaji, Doyle, Kerrie , Driscoll, Tim , Dubljanin, Eleonora , Adema, Bereket Duko , Eagan, Arielle Wilder , Elemineh, Demelash Abewa , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Eyawo, Oghenowede , Faris, Pawan , Faro, André , Farzadfar, Farshad , Fereshtehnejad, Seyed-Mohammad , Fernandes, Eduarda , Ferrara, Pietro , Fischer, Florian , Foláyan, Morẹ́nikẹ́ Oluwátóyìn , Fomenkov, Artem Alekseevich , Francis, Joel M , Fukumoto, Takeshi , Geberemariyam, Biniyam Sahiledengle, Gebremariam, Hadush, Gebremedhin, Ketema Bizuwork , Gebremeskel, Leake , Gebremeskel, Gebreamlak Gebremedhn , Gebremichael, Berhe , Geta, Birhanu, Ghafourifard, Mansour , Ghamari, Farhad , Gheshlagh, Reza Ghanei , Gholamian, Asadollah , Gilani, Syed Amir , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Guo, Yuming , Haagsma, Juanita A. , Hall, Brian J. , Hamadeh, Randah R , Hassan, Shoaib, Hassen, Hamid Yimam , Havmoeller, Rasmus, Heydarpour, Fatemeh , Hı́jar, Martha , Ho, Hung Chak , Hoang, Chi Linh , Hole, Michael K., Hossain, Naznin , Hosseinzadeh, Mehdi , Hostiuc, Sorin , Ibitoye, Segun Emmanuel , Inbaraj, Leeberk Raja , Irvani, Seyed Sina Naghibi , Islam, M. Mofizul , Islam, Sheikh Mohammed Shariful , Ivers, Rebecca , Jahani, Mohammad Ali, Jakovljević, Mihajlo , Jayaraman, Sudha , Jha, Ravi Prakash , John-Akinola, Yetunde O. , Joseph, Nitin , Joukar, Farahnaz, Jürisson, Mikk , Kahsay, Amaha , Kalankesh, Leila R , Kalhor, Rohollah , Kamil, Teshome Abegaz, Kapoor, Neeti , Karami, Manoochehr , Kasaeian, Amir , Kassaye, Hagazi Gebremedhin, Kavetskyy, Taras , Kayode, Gbenga A , Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khalil, Ibrahim A, Khalilov, Rovshan , Khan, Maseer , Khan, Ejaz Ahmad , Khan, Junaid , Khanna, Tripti, Khundkar, Roba , Kiirithio, Daniel N, Kim, Yun Jin , Kısa, Sezer , Kısa, Adnan , Komaki, Hamidreza , Kondlahalli, Shivakumar K M, Koolivand, Ali , Korshunov, Vladimir Andreevich , Kraemer, Moritz U. G. , Krishan, Kewal , Defo, Barthélémy Kuate , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Manasi , Kumar, Vivek , Kumar, Narinder , Kumaresh, Girikumar, Lami, Faris , Lasrado, Savita , Leasher, Janet L , Li, Shanshan , Liu, Xuefeng , Lyons, Ronan A , Machado, Daiane Borges , Madadin, Mohammed , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Majeed, Azeem , Maled, Venkatesh , Manafi, Navid , Manafi, Amir , Manda, Ana-Laura, Mansour-Ghanaei, Fariborz, Mason‐Jones, Amanda J. , Masoumi, Seyedeh Zahra , Massenburg, Benjamin B. , Maulik, Pallab K , Mehndiratta, Man Mohan, Melketsedik, Zeleke Aschalew , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Merie, Hayimro Edemealem , Miazgowski, Bartosz , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Mithra, Prasanna , Moghadaszadeh, Masoud, Mohammad, Yousef , Mohammadian-Hafshejani, Abdollah , Mohammed, Shafiu , Mohammed, Jemal , Bandpei, Mohammad Ali Mohseni, Molokhia, Mariam , Monasta, Lorenzo , Moodley, Yoshan , Moradi, Masoud , Moradi, Ghobad , Morawska, Lídia , Velásquez, Ilais Moreno , Mossie, Tilahun Belete , Musa, Kamarul Imran , Mustafa, Ghulam , Naderi, Mehdi , Nagarajan, Ahamarshan Jayaraman , Naik, Gurudatta , Naimzada, Mukhammad David , Nangia, Vinay, Nascimento, Bruno Ramos , Naserbakht, Morteza , Ndwandwe, Duduzile , Negoi, Ionuţ , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nguyen, Diep Ngoc , Nikbakhsh, Rajan , Ningrum, Dina Nur Anggraini , Nnaji, Chukwudi A , Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Oghenetega, Onome Bright , Olagunju, Andrew T , Olagunju, Tinuke O , Bali, Ahmed Omar , Onwujekwe, Obinna , Orpana, Heather , Otstavnov, Nikita , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakshir, Keyvan , Panda‐Jonas, Songhomitra, Park, Eun‐Kee , Patel, Sangram Kishor , Pathak, Ashish , Pati, Sanghamitra , Paulos, Kebreab , Pepito, Veincent Christian Filipino , Полибин, Р. В. , Polinder, Suzanne, Pourmalek, Farshad , Pourshams, Akram , Poustchi, Hossein, Prakash, Swayam , Pribadi, Dimas Ria Angga , Puri, Parul , Syed, Zahiruddin Quazi, Rabiee, Navid , Radfar, Amir , Rafay, Anwar, Rafiee, Ata , Rafiei, Alireza , Rahim, Fakher , Rahman, Muhammad Aziz , Rajabpour-Sanati, Ali, Rajati, Fatemeh , Rakovac, Ivo , Rao, Sowmya J, Rashedi, Vahid , Rawal, Lal , Rawassizadeh, Reza , Renjith, Vishnu , Resnikoff, Serge , Rezapour, Aziz, Rickard, Jennifer , Saddik, Basema , Safdarian, Mahdi , Sajadi, S. Mohammad , Salamati, Payman, Salem, Marwa Rashad , Salem, Hosni , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Schwebel, David C. , Seedat, Soraya , Senthilkumaran, Subramanian , Seyedmousavi, Seyedmojtaba , Sha, Feng , Shaahmadi, Faramarz , Shaikh, Masood Ali , Shams-Beyranvand, Mehran , Shigematsu, Mika, Shin, Jae Il , Shiri, Rahman , Sigfúsdóttir, Inga Dóra, Singh, Pankaj Kumar , Sinha, Dhirendra Narain , Soriano, Joan B. , Soyiri, Ireneous N , Sufiyan, Mu’awiyyah Babale , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Wogayehu, Biruk , Tefera, Yibekal Manaye , Tekulu, Gebretsadkan Hintsa , Kassie, Ayenew , Титова, М. В. , Tlaye, Kenean Getaneh , Tohidinik, Hamid Reza , Topór-Mądry, Roman , Tripathy, Jaya Prasad , Tsai, Alexander C. , Tsatsakis, Aristidis , Car, Lorainne Tudor , Ullah, Irfan , Ullah, Saif , Upadhyay, Era , Valdéz, Pascual , Violante, Francesco Saverio , Waheed, Yasir , Wang, Yuan‐Pang , Wiangkham, Taweewat , Wolde, Haileab Fekadu , Woldeyes, Dawit Habte , Wu, Ai-Min, Wyper, Grant M. A. , Yadav, Rajaram , Yadollahpour, Ali , Yano, Yuichiro , Yaya, Sanni , Yazdi‐Feyzabadi, Vahid , Ye, Pengpeng , Yisma, Engida , Yoon, Seok‐Jun , Youm, Yoosik , Younis, Mustafa Z , Yousefi, Zabihollah , Yu, Yong , Moghadam, Telma Zahirian , Zaman, Sojib Bin , Zarei, Fatemeh , Zhang, Zhi-Jiang, Zhang, Yunquan , Zodpey, Sanjay , Dandona, Rakhi , Dharmaratne, Samath Dhamminda , Hay, Simon I , Mokdad, Ali H. , Reiner, Robert C. , Vos, Theo , Topór‐Mądry, Roman , Feyissa, Garumma Tolu , Haghparast‐Bidgoli, Hassan , Kumar, G Anil , Zahiruddin, Quazi Syed , Dianatinasab, Mostafa , Sanati, Ali Rajabpour , Baig, Atif Amin , Kumar, Vivek , Castaldelli-Maia, João M , Farzadfar, Farshad , Shin, Jae I L , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Bhagavathula, Akshaya Srikanth , Belete, T , Liu, Zichen , Roberts, Nicholas L S , Henry, Nathaniel J , Abdollahpour, Ibrahim , Adsuar, José Carmelo , Ahmed, Muktar Beshir , Ahmed, Rushdiá , Alghnam, Suliman Abdullah , Ali, Saqib , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Antonio, Carl Abelardo T. , Arab-Zozani, Morteza , Asaad, Malke , Balachandran, Arun , Banach, Maciej , Bayati, Mohsen , Bazargan‐Hejazi, Shahrzad , Bedi, Neeraj , Behzadifar, Masoud , Benseñor, Isabela M. , Boloor, Archith , Borges, Guilherme , Boufous, Soufiane , Chatziralli, Irini , Cicuttini, Flavia , Coelho, João M, Dahlawi, Saad M A , Daryani, Ahmad , Demeke, Feleke Mekonnen , Forooshani, Zahra Sadat Dibaji, Do, Hoa , Duko, Bereket , El-Jaafary, Shaimaa I , Zaki, Maysaa El Sayed , Eskandarieh, Sharareh , Foroutan, Masoud , Franklin, Richard C. , Gebremariam, Hadush, Gedefaw, Getnet , Bante, Agegnehu , Gill, Tiffany K. , Goudarzian, Amir Hossein , Grivna, Michal , Guimarães, Rafael Alves , Gupta, Gaurav Kumar , Hamidi, Samer , Handiso, Demelash Woldeyohannes , Haro, Josep María , Hasanzadeh, Amir , Hassanipour, Soheil , Hassankhani, Hadi , Hendrie, Delia V. , Holla, Ramesh , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jalilian, Farzad , Jayatilleke, Achala Upendra , Jonas, Jost B , Jones, Kelly , Jozwiak, Jacek Jerzy , Jungari, Suresh Banayya , Kabir, Ali , Kanchan, Tanuj , Khalil, Ibrahim A, Khazaei, Salman , Khazaie, Habibolah , Kim, Young‐Eun , Kim, Daniel , Shivakumar, KM , Koyanagi, Ai , Kumar, Nithin , Lansingh, Van Charles , Latifi, Arman , Lauriola, Paolo , Vecchia, Carlo La , Lee, Shaun Wen Huey , Lopez, Alan D , Lotufo, Paulo A. , Malta, Déborah Carvalho , Manjunatha, Narayana , Mansour‐Ghanaei, Fariborz , Mansournia, Mohammad Alì , Maravilla, Joemer Calderon , Aschalew, Zeleke , Meštrović, Tomislav , Mirică, Andreea , Mirzaei-Alavijeh, Mehdi, Moazen, Babak , Mohamadi, Efat , Darwesh, Aso Mohammad , Mohammadpourhodki, Reza , Mohebi, Farnam , Moradi‐Lakeh, Maziar , Moradzadeh, Rahmatollah , Morrison, Shane D. , Muluneh, Atalay Goshu , Najafi, Farid , Nayak, Vinod C , Nazari, Javad , Nguyen, Trang Huyen , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Ota, Erika , Peden, Amy E. , Pereira, Jeevan , Phillips, Michael , Rabiee, Mohammad , Rahimi, Siavash , Rastogi, Prateek , Rathi, Priya , Rawaf, Salman , Ribeiro, Ana Isabel , Ríos-González, Carlos Miguel , Roever, Leonardo , Ronfani, Luca , Roshandel, Gholamreza , Safarpour, Hamid , Salamati, Payman, Santric-Milicevic, Milena M , Sarker, Abdur Razzaque , Sayyah, Mehdi , Shahabi, Saeed , Sheikh, Aziz , Siabani, Soraya , Singh, Ambrish , Soheili, Amin , Sorrie, Muluken Bekele , Stokes, Mark Andrew , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Thapar, Rekha , Tran, Khanh Bao , Tran, Bach Xuan , Unnikrishnan, Bhaskaran , Uthman, Olalekan Abdulrahman , Vasankari, Tommi Juhani , Veisani, Yousef , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Wondmeneh, Temesgen Gebeyehu , Wondmieneh, Adam Belay , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zandian, Hamed , Zhang, Zhi‐Jiang , Ziapour, Arash , Pigott, David M. , Olagunju, Andrew T , Baig, Atif Amin , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

Injury Prevention | August 24, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i125-i153

10.1136/injuryprev-2019-043531 | PMID 32839249 Get It

Background While there is a long history of measuring death and disability from injuries, modern research methods must account for the wide spectrum of disability that can occur in an injury, and must provide estimates with sufficient demographic, geographical and temporal detail to be useful for policy makers. The Global Burden of Disease (GBD) 2017 study used methods to provide highly detailed estimates of global injury burden that meet these criteria. Methods In this study, we report and discuss the methods used in GBD 2017 for injury morbidity and mortality burden estimation. In summary, these methods included estimating cause-specific mortality for every cause of injury, and then estimating incidence for every cause of injury. Non-fatal disability for each cause is then calculated based on the probabilities of suffering from different types of bodily injury experienced. Results GBD 2017 produced morbidity and mortality estimates for 38 causes of injury. Estimates were produced in terms of incidence, prevalence, years lived with disability, cause-specific mortality, years of life lost and disability-adjusted life-years for a 28-year period for 22 age groups, 195 countries and both sexes. Conclusions GBD 2017 demonstrated a complex and sophisticated series of analytical steps using the largest known database of morbidity and mortality data on injuries. GBD 2017 results should be used to help inform injury prevention policy making and resource allocation. We also identify important avenues for improving injury burden estimation in the future.
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database
Wagner, Dorothea , André, Thierry , Dixon, Jesse G. , Haller, Daniel G. , Allegra, Carmen J. , Gramont, Aimery de , VanCutsem, Eric, George, Thomas J. , Twelves, Christopher , Taı̈eb, Julien , Blanke, Charles D. , Francini, Edoardo , Yothers, Greg , Seitz, Jean François, Marsoni, Silvia , Goldberg, Richard M. , Shi, Qian , George, Thomas J , André, Thierry , Shi, Qian , Yothers, Greg , Taieb, Julien , Marsoni, Silvia , Dixon, Jesse G , Grothey, Axel , Wolmark, Norman , Alberts, Steven R. , O’Connell, Michael J. , Saltz, Leonard B. , Kerr, Rachel

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 19, 2020 | Volume: 113 | Issue: 4 | Pages: 400-407

10.1093/jnci/djaa124 | PMID 32835356 Get It

Abstract Background Adjuvant chemotherapy is a standard treatment option for patients with stage III and high-risk stage II colon cancer. Sex is one of several factors responsible for the wide inter-patient variability in drug responses. Amalgamated data on the effect of sex on the toxicity of current standard adjuvant treatment for colorectal cancer are missing. Methods The objective of our study was to compare incidence and severity of major toxicities of fluoropyrimidine- (5FU or capecitabine) based adjuvant chemotherapy, with or without oxaliplatin, between male and female patients after curative surgery for colon cancer. Adult patients enrolled in 27 relevant randomized trials included in the ACCENT (Adjuvant Colon Cancer End Points) database, a large, multi-group, international data repository containing individual patient data, were included. Comparisons were conducted using logistic regression models (stratified by study and treatment arm) within each type of adjuvant chemotherapy (5FU, FOLFOX, capecitabine, CAPOX, and FOLFIRI). The following major toxicities were compared (grade III or IV and grade I-IV, according to National Cancer Institute Common Terminology Criteria [NCI-CTC] criteria, regardless of attribution): nausea, vomiting, nausea or vomiting, stomatitis, diarrhea, leukopenia, neutropenia, thrombocytopenia, anemia, and neuropathy (in patients treated with oxaliplatin). Results Data from 34 640 patients were analyzed. Statistically significant and clinically relevant differences in the occurrence of grade III or IV nonhematological {especially nausea (5FU: odds ratio [OR] = 2.33, 95% confidence interval [CI] = 1.90 to 2.87, P < .001; FOLFOX: OR = 2.34, 95% CI = 1.76 to 3.11, P < .001), vomiting (5FU: OR = 2.38, 95% CI = 1.86 to 3.04, P < .001; FOLFOX: OR = 2.00, 95% CI = 1.50 to 2.66, P < .001; CAPOX: OR = 2.32, 95% CI = 1.55 to 3.46, P < .001), and diarrhea (5FU: OR = 1.35, 95% CI = 1.21 to 1.51, P < .001; FOLFOX: OR = 1.60, 95% CI = 1.35 to 1.90, P < .001; FOLFIRI: OR = 1.57, 95% CI = 1.25 to 1.97, P < .001)} as well as hematological toxicities (neutropenia [5FU: OR = 1.55, 95% CI = 1.37 to 1.76, P < .001; FOLFOX: OR = 1.96, 95% CI = 1.71 to 2.25, P < .001; FOLFIRI: OR = 2.01, 95% CI = 1.66 to 2.43, P < .001; capecitabine: OR = 4.07, 95% CI = 1.84 to 8.99, P < .001] and leukopenia [5FU: OR = 1.74, 95% CI = 1.40 to 2.17, P < .001; FOLFIRI: OR = 1.75, 95% CI = 1.28 to 2.40, P < .001]) were observed, with women being consistently at increased risk. Conclusions Our analysis confirms that women with colon cancer receiving adjuvant fluoropyrimidine-based chemotherapy are at increased risk of toxicity. Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation.